[go: up one dir, main page]

DE60143911D1 - Antitumorzusammensetzungen welche ecteinascidin 743 enthalten - Google Patents

Antitumorzusammensetzungen welche ecteinascidin 743 enthalten

Info

Publication number
DE60143911D1
DE60143911D1 DE60143911T DE60143911T DE60143911D1 DE 60143911 D1 DE60143911 D1 DE 60143911D1 DE 60143911 T DE60143911 T DE 60143911T DE 60143911 T DE60143911 T DE 60143911T DE 60143911 D1 DE60143911 D1 DE 60143911D1
Authority
DE
Germany
Prior art keywords
ecteinascidine
compositions containing
antitumor compositions
antitumor
tumour
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60143911T
Other languages
English (en)
Inventor
Naoto Takahashi
Steve Weitman
Incalci Maurizio D
Glynn Thomas Faicloth
Rafaella Giavazzi
Andreas Gescher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27399908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60143911(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmamar SA filed Critical Pharmamar SA
Application granted granted Critical
Publication of DE60143911D1 publication Critical patent/DE60143911D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60143911T 2000-11-06 2001-11-06 Antitumorzusammensetzungen welche ecteinascidin 743 enthalten Expired - Lifetime DE60143911D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24623300P 2000-11-06 2000-11-06
US24809500P 2000-11-13 2000-11-13
US34598201P 2001-10-19 2001-10-19
PCT/GB2001/004902 WO2002036135A2 (en) 2000-11-06 2001-11-06 Compositions for antitumour treatment containing ecteinascidin 743

Publications (1)

Publication Number Publication Date
DE60143911D1 true DE60143911D1 (de) 2011-03-03

Family

ID=27399908

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60143911T Expired - Lifetime DE60143911D1 (de) 2000-11-06 2001-11-06 Antitumorzusammensetzungen welche ecteinascidin 743 enthalten

Country Status (25)

Country Link
US (3) US20040108086A1 (de)
EP (1) EP1365808B1 (de)
JP (2) JP4391083B2 (de)
KR (1) KR100718946B1 (de)
CN (1) CN100374162C (de)
AT (1) ATE495793T1 (de)
AU (2) AU1249902A (de)
BG (1) BG107843A (de)
BR (1) BR0115162A (de)
CA (1) CA2428160C (de)
CY (1) CY1112361T1 (de)
CZ (1) CZ20031327A3 (de)
DE (1) DE60143911D1 (de)
DK (1) DK1365808T3 (de)
EA (1) EA005564B1 (de)
HK (1) HK1060067A1 (de)
HU (1) HUP0400648A3 (de)
IL (1) IL155781A0 (de)
MX (1) MXPA03003975A (de)
NO (1) NO329981B1 (de)
NZ (1) NZ525730A (de)
PL (1) PL361389A1 (de)
PT (1) PT1365808E (de)
SK (1) SK287901B6 (de)
WO (1) WO2002036135A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
CN100374162C (zh) * 2000-11-06 2008-03-12 法马马有限公司 海鞘素－743在制备用于治疗肿瘤的药剂中的应用
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
WO2003039571A1 (en) * 2001-10-19 2003-05-15 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
DE602004016376D1 (de) 2003-11-13 2008-10-16 Pharma Mar Sau Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
EP1691809A1 (de) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Kombinationstherapie mit verwendung von et-743 und paclitaxel zur behandlung von krebs
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
MX2007000360A (es) * 2004-07-09 2007-06-12 Pharma Mar Sa Marcadores moleculares de pronostico.
AU2005288696A1 (en) * 2004-09-28 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
PL1827500T3 (pl) * 2004-10-26 2009-09-30 Pharma Mar Sa Pegylowana liposomalna doksorubicyna w kombinacji z ekteinascydyną 743
PT1658848E (pt) 2004-10-29 2007-11-05 Pharma Mar Sa Formulações contendo ecteinascidina e um dissacarídeo
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
AU2006318226A1 (en) * 2005-11-25 2007-05-31 Pharma Mar, S.A. Sociedad Unipersonal Use of PARP-1 inhibitors
WO2009050303A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for et-743 treatment
RU2605335C2 (ru) * 2010-11-12 2016-12-20 Фарма Мар, С.А. Комбинированная терапия противоопухолевым алкалоидом
GB201217439D0 (en) * 2012-09-28 2012-11-14 Topotarget As Combination therapy
WO2014165818A2 (en) 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions and methods for preventing and treating prostate cancer
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
CN109276719A (zh) * 2018-11-01 2019-01-29 中山万汉制药有限公司 含有奥利司他纳米粒与蛋白激酶抑制剂的组合物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
JP4562815B2 (ja) * 1997-05-21 2010-10-13 ジェネンテック， インコーポレイテッド トロンボポエチンの新規な投与
AU758100B2 (en) * 1998-04-06 2003-03-13 Board Of Trustees Of The University Of Illinois, The Semi-synthetic ecteinascidins
ES2239442T3 (es) * 1998-05-11 2005-09-16 Pharma Mar, S.A. Metabolitos de ecteinascidina 743.
JP2000081438A (ja) * 1998-06-25 2000-03-21 Sekisui Chem Co Ltd 被験者の癌化学療法による免疫機能低下の測定方法
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
CA2418320A1 (en) * 2000-08-11 2002-02-21 City Of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
CN100374162C (zh) * 2000-11-06 2008-03-12 法马马有限公司 海鞘素－743在制备用于治疗肿瘤的药剂中的应用
WO2002076459A1 (en) * 2001-03-06 2002-10-03 Bristol-Myers Squibb Company Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
JP4391038B2 (ja) * 2001-05-10 2009-12-24 パナソニック株式会社 電気炊飯器
WO2003039571A1 (en) * 2001-10-19 2003-05-15 Pharmamar S.A. Improved use of antitumoral compound in cancer therapy
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
DE602004016376D1 (de) * 2003-11-13 2008-10-16 Pharma Mar Sau Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
EP1691809A1 (de) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Kombinationstherapie mit verwendung von et-743 und paclitaxel zur behandlung von krebs
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
MX2007000360A (es) * 2004-07-09 2007-06-12 Pharma Mar Sa Marcadores moleculares de pronostico.
AU2005288696A1 (en) * 2004-09-28 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
PL1827500T3 (pl) * 2004-10-26 2009-09-30 Pharma Mar Sa Pegylowana liposomalna doksorubicyna w kombinacji z ekteinascydyną 743
PT1658848E (pt) * 2004-10-29 2007-11-05 Pharma Mar Sa Formulações contendo ecteinascidina e um dissacarídeo
AU2006318226A1 (en) * 2005-11-25 2007-05-31 Pharma Mar, S.A. Sociedad Unipersonal Use of PARP-1 inhibitors
CA2652035A1 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments

Also Published As

Publication number Publication date
US20090324744A1 (en) 2009-12-31
EA200300544A1 (ru) 2003-08-28
CA2428160A1 (en) 2002-05-10
KR100718946B1 (ko) 2007-05-16
BR0115162A (pt) 2003-10-21
NO20032027L (no) 2003-07-04
HK1060067A1 (en) 2004-07-30
HUP0400648A3 (en) 2012-09-28
JP2009114212A (ja) 2009-05-28
KR20030048127A (ko) 2003-06-18
ATE495793T1 (de) 2011-02-15
NO20032027D0 (no) 2003-05-06
CN1486193A (zh) 2004-03-31
US20040108086A1 (en) 2004-06-10
NO329981B1 (no) 2011-01-31
PL361389A1 (en) 2004-10-04
EA005564B1 (ru) 2005-04-28
JP4391083B2 (ja) 2009-12-24
WO2002036135A3 (en) 2003-04-10
JP2004517056A (ja) 2004-06-10
US20120107417A1 (en) 2012-05-03
EP1365808B1 (de) 2011-01-19
NZ525730A (en) 2004-12-24
EP1365808A2 (de) 2003-12-03
SK287901B6 (sk) 2012-03-02
CA2428160C (en) 2009-10-13
CY1112361T1 (el) 2015-12-09
SK5492003A3 (en) 2004-03-02
IL155781A0 (en) 2003-12-23
BG107843A (bg) 2004-06-30
AU1249902A (en) 2002-05-15
DK1365808T3 (da) 2011-05-16
PT1365808E (pt) 2011-04-08
CN100374162C (zh) 2008-03-12
AU2002212499B2 (en) 2006-11-02
MXPA03003975A (es) 2004-02-12
HUP0400648A2 (hu) 2004-06-28
WO2002036135A2 (en) 2002-05-10
CZ20031327A3 (cs) 2003-11-12

Similar Documents

Publication Publication Date Title
DE60143911D1 (de) Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
GEP20063799B (en) Tropane derivatives useful in therapy
BR9906581A (pt) Processo para administração de taxano encapsulado em lipossomos
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
TR200002786T2 (tr) Meloksikam için yeni galenik bir formülasyon.
NO20040096L (no) Taxol-forbedringsforbindelser
MY119403A (en) Novel compounds with analgesic effect.
MY132705A (en) Novel compounds with analgesic effect
CY1112753T1 (el) Θεραπευτικη αγωγη καρκινων του ανθρωπινου σωματος με τη χρηση toy ετ743
FI956014A0 (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
DE69531098D1 (de) Piperidine und pyrrolidine
SE9802208D0 (sv) Novel compounds
ATE194987T1 (de) Substituierte dibenzoxazepinverbindungen, pharmazeutische zusammensetzungen und anwendungsmethoden
DE602004016376D1 (de) Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
PT1030667E (pt) Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono
RS52011B (sr) Nova primena derivata taksoida
SE9802209D0 (sv) Novel compounds
GEP201606538B (en) Preoperative treatment of post operative pain
MX9203361A (es) Composiciones farmaceuticas que contienen cloruro de galio.
HK1077215A1 (en) A pharmaceutical composition for treatment of acute myocardial infarction
SE0004827D0 (sv) Therapeutic compounds
KR930702016A (ko) 골다공증 치료제
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
ATE464051T1 (de) Kombination aus levosimendan und einer kalziumquelle zur behandlung von herzinsuffizienz